What it is

Tesamorelin is a stabilized growth-hormone-releasing hormone (GHRH) analog used to study GH-axis output and visceral-adipose endpoints.

Also known as

Egrifta (brand context) · Stabilized GHRH analog · TH9507

Overview

Tesamorelin is a stabilized growth-hormone-releasing hormone (GHRH) analog used to study GH-axis output and visceral-adipose endpoints.

Laboratory interest includes IGF-1 pathway markers, body-composition measures, and GHRH-receptor pharmacology. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

• Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• GH-pulse and IGF-1 axis endpoints in GHRH models

• Visceral-adipose and trunk-fat research markers

• Body-composition readouts in GH-axis designs

• Lipid and metabolic co-markers where reported

• GHRH-receptor pharmacology versus other secretagogues

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

Week 1–2: GH-axis pulse and IGF-related markers beginning to register in short observation windows.

Week 3–4: Clearer GH/IGF pathway readouts and recovery-adjacent markers in research models.

Month 2–3: Body-composition and soft-tissue endpoints more apparent in extended preclinical designs.

Month 3–6: Sustained GH-axis and composition-related observations where protocols run longer.

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.